Curriculum
Module 09 · 55 min

Brain Fog, Mood and Sleep

Real, measurable, mostly transient — and frequently misdiagnosed as depression or early dementia.

Brain, mood & sleepPrimary care track
Module progress0%
Quiz 0/3Cards 0/5Claims 0/6
Learning objectives

By the end of this module you will be able to

  • L01Reassure accurately: processing speed and verbal memory dip during the transition and largely recover afterwards.
  • L02Identify risk factors for perimenopausal depression: prior depression, PMDD history, adverse life events, severe VMS.
  • L03Screen for obstructive sleep apnoea in midlife women, in whom presentation differs from men.
  • L04Explain when oestrogen may help mood and when an antidepressant is the correct first choice.
  • L05State the WHIMS finding and its implications for MHT initiation after 65.
Scope

Topics covered

01Objective cognitive findings across the transition and their trajectory
02The window of vulnerability for depression and who is at risk
03Distinguishing perimenopausal depression from major depressive disorder
04Sleep architecture, VMS-related awakenings and midlife obstructive sleep apnoea
05Antidepressants vs oestrogen: what the evidence supports for each
06WHIMS and why MHT is not a dementia prevention strategy
Module narrative

How this plays out in practice

Primary care view· your track

Name the cognitive symptom, quantify it briefly, and reassure with the trajectory data — much of the distress comes from fearing early dementia. Screen for depression, sleep apnoea (snoring, witnessed apnoeas, unrefreshing sleep, resistant hypertension) and alcohol. If VMS are driving night awakenings, treating VMS often resolves the daytime cognitive complaint without any cognition-specific intervention.

Specialist view

For perimenopausal depression, transdermal estradiol has RCT support for depressive symptoms in the perimenopause (Soares 2001; Gordon 2018), whereas postmenopausal major depression should be treated conventionally. Where both mood and VMS are present, an SSRI/SNRI may address both. Be alert to progestogen-related mood deterioration, which is agent-specific and often fixable by switching rather than stopping.

Advanced note

WHIMS is frequently over-generalised. It randomised women aged 65 and over to CEE ± MPA and found increased all-cause dementia in the combined arm. It cannot answer whether earlier initiation is neutral or protective. KEEPS-Cognitive and its continuation found no cognitive benefit or harm with early initiation over 4 years and at 10-year follow-up — evidence of neutrality in early initiators, not of protection.

Expected takeaways

What you should walk away believing

  • →SWAN's cognitive substudy demonstrated a measurable but small decline in processing speed and verbal memory during the transition, with recovery in postmenopause.
  • →The transition is a window of vulnerability for new and recurrent depression, especially with a prior history or PMDD.
  • →Sleep disruption is often multifactorial: VMS awakenings, primary insomnia, restless legs and undiagnosed OSA, which rises sharply after menopause.
  • →Oestrogen has evidence for depressive symptoms in the perimenopause but not in established postmenopausal major depression.
  • →WHIMS: MHT initiated after 65 increased dementia incidence — prevention is not an indication at any age.
Myth-buster

What patients — and colleagues — get wrong

The claim

“Menopausal brain fog is the start of dementia.”

Reality

Transition-related cognitive change is small, largely confined to processing speed and verbal learning, and improves postmenopause. It is worsened by poor sleep and untreated VMS. That said, new persistent decline in a woman over 50 still deserves proper assessment rather than reflexive attribution to hormones.

Graded claims

Evidence grading for this module

B

Cognitive performance dips during the transition and recovers postmenopause

Supported in defined populations — SWAN cognitive substudy, longitudinal within-woman design.

B

The perimenopause is a window of increased depression risk

Supported in defined populations — Harvard Study of Moods and Cycles, SWAN, Penn Ovarian Aging Study.

B

Transdermal estradiol reduces depressive symptoms in perimenopausal women

Supported in defined populations — Multiple small RCTs including Gordon 2018 prevention trial.

B

MHT started after age 65 increases dementia risk

Supported in defined populations — WHIMS — combined arm; oestrogen-alone arm directionally similar but non-significant.

F

MHT prevents Alzheimer's disease

Refuted or actively misleading — No supporting RCT evidence; not an indication.

B

Obstructive sleep apnoea prevalence increases after menopause

Supported in defined populations — Consistent cohort data; often missed because presentation differs from men.

Evidence summary

Graded claims, key takeaways and sources for this module.

Open printable summary
Clinical vignettes

Apply it in clinic

'I think I have early dementia'

A 51-year-old teacher is frightened by word-finding lapses in class. Sleep is broken by night sweats 5 nights per week. Mood is low but she has no prior psychiatric history. Cognitive screening is normal.

Most appropriate plan?

Self-assessment

Check your recall

Q1

A 50-year-old reports word-finding difficulty and poor concentration with 6 night sweats nightly. Best first step?

Q2

Which patient is at highest risk of perimenopausal depression?

Q3

WHIMS demonstrated that:

Flashcards

Retrieval practice

Card 1 / 5
Reviewed 0 / 5
Glossary

Terms used in this module

WHIMS
Women's Health Initiative Memory Study — MHT in women aged 65+, showing increased all-cause dementia in the combined arm.
KEEPS-Cog
Cognitive substudy of the Kronos Early Estrogen Prevention Study; neutral cognitive findings with early initiation.
Allopregnanolone
Neuroactive progesterone metabolite with GABA-A agonist activity — the basis of micronised progesterone's sedative effect.
Primary sources

Read the evidence yourself